Atheroembolic disease following administration of tissue plasminogen activator (TPA).
Atheroembolic disease is an uncommon condition with many interesting manifestations and has been reported following various procedures. Its occurrence following thrombolytic therapy is extremely rare, with only a few case reports in the literature. However, with a widespread application of thrombolysis in patients with acute myocardial infarction, its incidence is likely to increase and therefore this entity needs to be recognized. Early recognition of the illness may help avoid further expensive and unnecessary investigations. We report two cases of atheroembolic disease following the administration of human recombinant tissue plasminogen activator (TPA).
Aggarwal
K
K
University of Missouri-Columbia, USA.
Tjahja
I E
IE
D000368:Aged; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy; D010960:Plasminogen Activators / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects; D015912:Thrombolytic Therapy / Q000009:adverse effects; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
D011994:Recombinant Proteins; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator